semaglutide 2.4 mg weekly A higher-dose of Wegovy has received final regulatory clearance in the EU, marking a significant step for obesity treatment. The approval allows physicians to prescribe a 7.2 dose, administered as Wegovy 2.4 mg/0.75 mL pre-filled

Key Takeaways Semaglutide pens are built to deliver fixed, full doses and lack any mechanism for safely measuring or administering partial amounts

Focus on Bland, Easy-to-Digest Foods When nausea is active, particularly in those first few days after injections, stick with gentle foods

While semaglutides primary role is to help you feel full sooner and stay satisfied longer, weight loss is the outcome that many people hope for

Weight Loss with Semaglutide Average loss: 1416% of body weight Key trial: STEP 1 (New England Journal of Medicine) Population: Obese individuals without diabetes Notable: Significant appetite suppression and better cardiometabolic parameters reported by most participants Weight Loss with Tirzepatide Average loss: 21% or more of body weight at highest dose (15 mg) Key trial: SURMOUNT-1 Population: Obese and overweight adults without diabetes Remarkable: Highest rate of any FDA-approved weight loss medication to date Clinical Insight: Tirzepatide always beats Semaglutide in weight reduction

Healthcare providers usually monitor lipid panels at baseline and after 3-6 months to assess treatment response